DNA sequencing

Phibro Animal Health Corporation Announces the Appointment of Alejandro Bernal to Its Board of Directors and Declares Quarterly Dividend

Retrieved on: 
Monday, February 6, 2023
Defense, Consumer, Agriculture, Pets, Natural Resources, Veterans, MBA, Senior, Master of Business Administration, DVM, III, DNA sequencing, University of Caldas, Veterinary medicine, NGS, Alliance Manchester Business School, PAHC, Business administration, Zoetis, Liquid biopsy, MS, Cancer, Universidad de los Andes, Management, Physiology, Mars

The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately.

Key Points: 
  • The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately.
  • His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors.
  • Prior to Mars, Mr. Bernal worked 17 years for Zoetis (formerly Pfizer Animal Health), and was a member of the Executive Team for 10 years.
  • Mr. Bernal is qualified to serve on our Board of Directors due to his extensive management and leadership experience in all facets of the animal health industry, including in corporate strategy and business development.

U.S. Carrier Screening Market to Reach USD 2.14 Billion, by 2031 at 14.4% CAGR: Allied Market Research

Retrieved on: 
Tuesday, February 14, 2023
DNA, Polymerase chain reaction, Government, Hospital, Investment, Chromosome, Diagnosis, Cystic fibrosis, DSM-IV codes, Patient, Pregnancy, National Virus Reference Laboratory, Genetic counseling, Growth, Anti-transglutaminase antibodies, Prevalence, Genetic disorder, DNA sequencing, Vaccine

PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031.
  • By type, the expanded carrier screening segment held the major share in 2021, accounting for more than two-fifths of the U.S. carrier screening market revenue.
  • By technology, the DNA sequencing segment accounted for the highest revenue in 2021, contributing to nearly two-fifths of the U.S. carrier screening market share.

U.S. Carrier Screening Market to Reach USD 2.14 Billion, by 2031 at 14.4% CAGR: Allied Market Research

Retrieved on: 
Tuesday, February 14, 2023
DNA, Polymerase chain reaction, Government, Hospital, Investment, Chromosome, Diagnosis, Cystic fibrosis, DSM-IV codes, Patient, Pregnancy, National Virus Reference Laboratory, Genetic counseling, Growth, Anti-transglutaminase antibodies, Prevalence, Genetic disorder, DNA sequencing, Vaccine

PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031.
  • By type, the expanded carrier screening segment held the major share in 2021, accounting for more than two-fifths of the U.S. carrier screening market revenue.
  • By technology, the DNA sequencing segment accounted for the highest revenue in 2021, contributing to nearly two-fifths of the U.S. carrier screening market share.

Single Cell Analysis Market To Reach USD 13.62 Billion by 2031, Growing at a CAGR of 17.8%| Valuates Reports

Retrieved on: 
Thursday, February 9, 2023
DNA, B cell, Polymerase chain reaction, Medicine, Flow cytometry, Molecular biology, TME, DNA sequencing, Diagnosis, Mass spectrometry, NGS, PCR, Medication, Stem, Neurology, Test management, Oncology, Single-cell analysis, Incidence, Escape Room, RNA, Cell, Research, Analysis, Tumor microenvironment, USD, RNA-Seq, Immune system, Consumables, Growth, IVF, Viral Research and Diagnostic Laboratories, CELL, Genomics, Neoplasm, Environment, Prevalence, COVID-19, Hospital, Cancer, Gene expression, Pharmaceutical industry, Fine chemical, Vaccine, Medical imaging, Biotechnology, Immunology

The global Single Cell Analysis market size was valued at USD 2.64 billion in 2021, and is projected to reach USD 13.62 billion by 2031, growing at a CAGR of 17.8% from 2022 to 2031.

Key Points: 
  • The global Single Cell Analysis market size was valued at USD 2.64 billion in 2021, and is projected to reach USD 13.62 billion by 2031, growing at a CAGR of 17.8% from 2022 to 2031.
  • Additionally, the rise in customized medicine research, the expansion of stem cell research, and the rise in cancer prevalence all contribute to the growth of the single cell analysis market.
  • This factor is expected to drive the growth of the single cell analysis market.
  • SINGLE CELL ANALYSIS MARKET SHARE ANALYSIS:
    The single cell analysis market is segmented into consumables and instruments based on product.

Single Cell Analysis Market To Reach USD 13.62 Billion by 2031, Growing at a CAGR of 17.8%| Valuates Reports

Retrieved on: 
Thursday, February 9, 2023
DNA, B cell, Polymerase chain reaction, Medicine, Flow cytometry, Molecular biology, TME, DNA sequencing, Diagnosis, Mass spectrometry, NGS, PCR, Medication, Stem, Neurology, Test management, Oncology, Single-cell analysis, Incidence, Escape Room, RNA, Cell, Research, Analysis, Tumor microenvironment, USD, RNA-Seq, Immune system, Consumables, Growth, IVF, Viral Research and Diagnostic Laboratories, CELL, Genomics, Neoplasm, Environment, Prevalence, COVID-19, Hospital, Cancer, Gene expression, Pharmaceutical industry, Fine chemical, Vaccine, Medical imaging, Biotechnology, Immunology

The global Single Cell Analysis market size was valued at USD 2.64 billion in 2021, and is projected to reach USD 13.62 billion by 2031, growing at a CAGR of 17.8% from 2022 to 2031.

Key Points: 
  • The global Single Cell Analysis market size was valued at USD 2.64 billion in 2021, and is projected to reach USD 13.62 billion by 2031, growing at a CAGR of 17.8% from 2022 to 2031.
  • Additionally, the rise in customized medicine research, the expansion of stem cell research, and the rise in cancer prevalence all contribute to the growth of the single cell analysis market.
  • This factor is expected to drive the growth of the single cell analysis market.
  • SINGLE CELL ANALYSIS MARKET SHARE ANALYSIS:
    The single cell analysis market is segmented into consumables and instruments based on product.

Sequencing Reagents Market To Reach USD 15.9 Billion By 2028 With A CAGR Of 16.4%| Valuates Reports

Retrieved on: 
Friday, February 3, 2023
DNA, Mutation, Pulsus Group, DNA sequencing, Pharmacology, NGS, Third-generation sequencing, Projection, Medication, Oncology, Patient, RNA, Research, USD, Growth, Neoplasm, Sanger sequencing, Cancer, Fine chemical, Medical imaging

The global Sequencing Reagents Market size is estimated to be worth USD 5.5 billion in 2021 and is forecast to a readjusted size of USD 15.9 billion by 2028 with a CAGR of 16.4% during the review period.

Key Points: 
  • The global Sequencing Reagents Market size is estimated to be worth USD 5.5 billion in 2021 and is forecast to a readjusted size of USD 15.9 billion by 2028 with a CAGR of 16.4% during the review period.
  • The two main variables that will affect the growth of the sequencing reagents market are advances in sequencing techniques and falling costs for genetic sequencing.
  • Additionally, the Sequencing Reagents market is expanding at an accelerated rate due to the spike in the usage of sequencing techniques and different developments.
  • This factor is expected to drive the growth of the Sequencing Reagents market.

Center for Breakthrough Medicines Launches Precision Plasmids™ Manufacturing to Accelerate Advanced Therapies into the Clinic

Retrieved on: 
Thursday, February 2, 2023
Messenger, DNA sequencing, SVP, NGS, Maintenance, Precision, Quality management system, Plasmid, QMS, CAPA, CBM, NO, Tat, GMP, Education, Communities and Justice Directorates, CDMO, Vaccine

KING OF PRUSSIA, Pa., Feb. 2, 2023 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO), has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate plasmid on-demand for any company seeking to accelerate their path to clinic for cell and gene therapies. CBM offers NO WAIT TIMES for Precision Plasmids™ R&D grade for pre- and early clinical phases, and Precision Plasmids™ Pro grade for toxicology studies, Ph1-2 vector production, or as a starting material for mRNA. Both Precision Plasmids™ R&D and Pro are available now, while Precision Plasmids™ GMP grade will be available in April 2023.

Key Points: 
  • KING OF PRUSSIA, Pa., Feb. 2, 2023 /PRNewswire/ -- The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO), has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate plasmid on-demand for any company seeking to accelerate their path to clinic for cell and gene therapies.
  • Both Precision Plasmids™ R&D and Pro are available now, while Precision Plasmids™ GMP grade will be available in April 2023.
  • CBM Precision Plasmids™ are of the highest quality, confirmed by Next Generation Sequencing (NGS) to guarantee the reproducibility of vector-based therapies that are manufactured using plasmids.
  • Whether standalone starting material or within CBM's integrated Genesis Vector Manufacturing Solution™ , cell and gene therapy companies can start development and manufacturing today.

Body Fluid Collection and Diagnostic Market Report 2022: Sector to Expand by 7.87% Annually Through 2033

Retrieved on: 
Wednesday, January 25, 2023
Conditional sentence, USD, Integration, University, Ministry of Health, FISH, Collection, COVID, Incidence, Diagnosis, DSM-IV codes, Human, Polymerase chain reaction, Urine, Blood, DNA, DNA sequencing, Indian Council of Medical Research, Government, Partnership, Region, NGS, Polymerase, PCR, Congo, COVID-19, Ministry, Saliva, Growth, Chronic kidney disease, BD, Fluid mechanics, Cerebrospinal fluid, Fluorescence, Patient, Proteinuria, Laboratory, Infection, Democratic republic, In situ hybridization, Mindray, University of Tokyo, Medical research, Hematology, Tissue, DTC, Medical device, Pharmaceutical industry, Vaccine, Health

The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.

Key Points: 
  • The body fluid collection and diagnostic market size is estimated to be USD 30,525.12 million in 2022 and is expected to witness a CAGR of 7.87% during the forecast period 2023-2033.
  • A number of players directly sell DTC sample collection kits to consumers and then analyse the samples they collect.
  • Body fluid remains found at crime scenes are critical pieces of evidence for forensic investigators.
  • Body fluid testing has benefits for disease diagnosis and monitoring, including low cost, low invasiveness, and speedy sample collection and processing.

GTG to form Strategic Alliance with global testing leader QIAGEN

Retrieved on: 
Wednesday, February 1, 2023
Health, Family medicine, Automation, Large intestine, DNA, ASX, Genetypes, Commercial Operating System (COS), Software, Authorization, Colorectal cancer, Accreditation, QIAGEN, DNA sequencing, NGS, Genomics, Patient, Partnership, NATA, GTG, Precision medicine, Growth, Organization, Fine chemical

MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.

Key Points: 
  • MELBOURNE, Australia, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to announce that the Company is forming a strategic alliance with QIAGEN, a global leader in molecular testing with operations in 35 countries.
  • The partnership will further enhance GTG’s reputation as a regional leader in precision medicine in predicative and consumer genomics, utilizing QIAGEN technologies.
  • QIAGEN will support the Company through their global technical expertise and leadership, and work closely with GTG to bolster automation capability with hardware, reagents and panels, bringing best-in-class testing.
  • This strategic alliance will leverage QIAGEN testing technologies from Sample to Insight for multiple applications.

Integrated DNA Technologies Acquires ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation

Retrieved on: 
Tuesday, December 20, 2022
Oncology, Health, Technology, Other Technology, Genetics, Research, Science, NGS, Archery, IDT, Triangle Park (Quezon City), NYSE, RNA, RUO, Mills, CRISPR, Synthetic biology, Genomics, Multimedia, RNA interference, Infection, XGen Studios, Biomarker, PCR, Integrated DNA Technologies, GMP, Research, Cancer, ISO, Acquisition, DNA sequencing, AMP, Fine chemical

Integrated DNA Technologies, Inc. (IDT) today announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer®.

Key Points: 
  • Integrated DNA Technologies, Inc. (IDT) today announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer®.
  • The NGS research assays were formally known as Invitae’s Research Use Only (RUO) kitted solutions.
  • Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry.
  • IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference.